Cite
HARVARD Citation
Bissonnette, R. et al. (2018). Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). Journal of the European Academy of Dermatology and Venereology. pp. 1507-1514. [Online].